ARS Pharmaceuticals, Inc. is a biopharmaceutical company that specializes in the development of therapies for severe allergic reactions. The company's flagship product, neffy, is the first and only FDA-approved needle-free epinephrine nasal spray for the emergency treatment of Type I allergic reactions, such as anaphylaxis. By utilizing a proprietary absorption-enhancing technology, neffy offers a rapid, easy-to-use alternative to conventional epinephrine auto-injectors, addressing common patient hesitations associated with needle-based devices. Beyond its core focus on anaphylaxis, ARS Pharmaceuticals is advancing clinical development programs to expand the use of its intranasal epinephrine technology for other indications, including chronic spontaneous urticaria. The company operates primarily in the United States while advancing international regulatory approvals and commercialization through strategic partnerships in Europe, Japan, and other global markets.
